Gan & Lee Pharmaceuticals upholds a culture of "Science and Excellence", adheres to the principle of "Clinical Value-Oriented, Innovation-Driven Development", and is driven by independent innovation to continuously build a full-chain R&D system covering drug discovery, candidate molecule screening, process development, clinical development, and industrialization.

With over two decades of expertise in diabetes mellitus and metabolic diseases, the company has developed systematic R&D capabilities in the insulin field, ranging from long-acting, rapid-acting, and premixed products to new-generation weekly insulin formulations and combination formulations. Meanwhile, it continues to expand cutting-edge technology platforms such as peptides, proteins, and proteolysis-targeting chimeras (PROTACs), and is also venturing into antibodies and AI-enabled drug discovery and development. The company is progressively expanding into therapeutic areas such as obesity and oncology, while building differentiated R&D capabilities to support the global development of innovative medicines.